TRANSCATHETER AORTIC VALVE REPLACEMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Regional Analysis

To learn more about this report, Request sample copy

Dominating Region: North America

North America dominates the transcatheter aortic valve replacement market with an estimated share of 39.2% in 2024. This can be attributed to the strong presence of major medical device manufacturers, supportive reimbursement policies, high adoption rates among the aging population, and continual technological advancements. Key players like Medtronic and Edwards Lifesciences have contributed to the extensive availability of innovative treatment options.

Fastest-Growing Region: Asia Pacific

The Asia Pacific region exhibits the fastest growth, driven by increasing healthcare expenditures, rapid economic expansion, growing medical tourism, and government efforts to enhance accessibility of critical cardiac procedures. Countries like India and China are key focus areas for leading global companies like Abbott Laboratories looking to tap into untapped market potential.

Transcatheter Aortic Valve Replacement Market Outlook for Key countries

High Prevalence of Aortic Regurgitation in the U.S.

The U.S. leads in managing aortic regurgitation due to its high prevalence of the condition of aortic regurgitation (AR). For instance, the article "Aortic Regurgitation," published by StatPearls in April 2022 reported that the prevalence of aortic regurgitation in the U.S. ranges between 4.9% and 10.0%. Additionally, it highlighted that men (13.0%) are more likely to experience aortic regurgitation compared to women (8.5%).

Clinical Trials Driving Transcatheter Aortic Valve Replacement Adoption in the U.K.

The U.K. transcatheter aortic valve replacement industry is shaped by ongoing research and clinical trials. For example, the UK-TAVI trial, conducted in September 2022 by the National Institutes of Health (NIH), compared the outcomes of TAVR and surgical aortic valve replacement in patients over 70 with moderate operative risk. These trials play a vital role in evaluating safety and efficacy, influencing the integration of TAVR into clinical practice in the U.K.

Innovation in TAVR Technology and Accessibility in China

China’s transcatheter aortic valve replacement industry is experiencing growth driven by advancements in valve technology and procedural techniques. For instance, in August 2021, Peijia Medical launched its first and subsequent generations of TAVR, transcatheter aortic valve replacement products after receiving regulatory approval in China. These innovations improve procedural success, expand patient eligibility, and enhance access to minimally invasive treatments for severe aortic valve diseases.

Public Insurance Expanding Access to TAVR Treatments in Brazil

Brazil’s transcatheter aortic valve replacement market is boosted by comprehensive public insurance and efforts to expand access to under-served patient segments. Local medtech firms contribute to this progress. For instance, in January 2020, according to National Institutes of Health (NIH), as of 2020, Brazil's public health system, known as the Sistema Único de Saúde (SUS), covered about 80.8% of heart surgeries, including TAVR, ensuring access to care for elderly patients with severe aortic stenosis who often face financial constraints.